Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
European Journal of Cancer（2021）
摘要
Image 1
更多查看译文
关键词
Chemo-hormonal therapy,Combination therapy,Docetaxel,Enzalutamide,Metastatic castration-resistant prostate cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要